Sensyne Health the British clinical AI technology company has signed a non-exclusive agreement with Jefferson Health, one of the largest healthcare providers in Pennsylvania and New Jersey.
The agreement is to evaluate the clinical and commercial potential of Sensyne Health’s GDm-Health™ digital therapeutic in the Jefferson Health system. GDm-Health™ is a patient-clinician software system for the data-driven management of gestational diabetes mellitus (GDM).
Under the terms of the agreement, Sensyne Health will collaborate with Jefferson Health’s Department of Obstetrics and Gynaecology on a 12-month multi-phase Clinical and Health Economic Evaluation of the GDm-Health™ product in the Jefferson Health System Hospitalsin Pennsylvania and New Jersey. Sensyne Health will have the right to analyse, using its proprietary clinical AI technology, the anonymised and de-identified patient data generated during the evaluation to help uncover new insights and address areas of unmet medical need in women’s health.
Lord Paul Drayson, CEO of Sensyne Health, said: “We are delighted to be working with one of the fastest growing and most innovative healthcare providers in the United States to evaluate GDm-Health in the US market, a product that was invented and has proven to be effective in the UK’s National Health Service. We hope that this is the start of a long partnership that forms a new trans-Atlantic bridge for data-driven healthcare innovations to be developed between the United Kingdom and the United States of America for the benefit of our patients.“
Stephen K. Klasko, MD, MBA, President of Thomas Jefferson University and CEO of Jefferson Health “Creative collaborations across the globe will speed the future of augmented intelligence in healthcare. As an obstetrician, I’m especially delighted that Jefferson Health will work with Sensyne from the UK to help mothers with gestational diabetes.”
